Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pagibaximab for prevention of staphylococcal sepsis in VLBW neonates
NCT00646399Phase 3Completed
- Sponsor
- Biosynexus Incorporated
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in staphylococcal sepsis comparing Pagibaximab with Placebo (2 arms). Primary endpoint: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35 at 35 days. Started Mar 2009; status: completed.
02
Drugs
pagibaximab
03
Conditions
staphylococcal sepsis
Beyond the preview
Go deeper on NCT00646399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646399.